MS
COGT icon

Maven Securities’s Cogent Biosciences COGT Stock Holding History

Maven Securities’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-82,800
Closed -$2.94M – 424
2025
Q4 		$2.94M Buy
+82,800
New +$2.33M 0.06% 258
2021
Q2 		– Sell
-3,519
Closed -$31K – 1098
2021
Q1 		$31K Buy
+3,519
New +$33.9K ﹤0.01% 1121

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Maven Securities's COGT Position: Q1 2026 in Review

Maven Securities sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 82,800 shares — an estimated $2.94M sold.

Maven Securities first reported a position in COGT in Q1 2021 and held it in 2 quarters. The position peaked at $2.94M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Maven Securities reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
  • Maven Securities sold 82,800 Cogent Biosciences shares in Q1 2026, an estimated $2.94M.
  • Maven Securities first reported a position in Cogent Biosciences in Q1 2021 and held it in 2 quarters.
  • Maven Securities's Cogent Biosciences position peaked at $2.94M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.